Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

China's 3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin After U.S. Delays

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Canada's Isotechnika Pharma has signed a new deal with Chinese drug maker 3SBio on the development and commercialization of Isotechnika's voclosporin, which helps suppress the immune system's rejection of transplanted organs

You may also be interested in...



From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.

From Biosimilars To Corporate Venture: China's Top Biotech Takes Another Step

3SBio Inc.'s success with a biosimilar of erythropoietin Epogen has spurred the Chinese company to form a RMB 250 million venture fund with China Medical City, an up-and-coming science and technology park that is backed by China's national government.

Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt

"Several outstanding issues" forced FDA to cancel the meeting, the agency said.

UsernamePublicRestriction

Register

SC075748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel